SuperworthChemomab Therapeutics EPS CMMB
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Mar 31, 2023
- $0.25
- Latest quarter, Q1 FY23
- $0.16
- +82% on a year earlier
- Fiscal year 2022
- $0.18
- +159% on the year before
Chemomab Therapeutics' earnings per share was $0.25 over the twelve months to Mar 31, 2023, up 121% on a year earlier.
In its latest quarter, Q1 FY23, it was $0.16, up 82% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2022 | $0.18 | +159% |
| FY2021 | $0.07 | n/a |
| FY2019 | −$53.76 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY23 | $0.16 | +82% | $0.25 | |
| Q4 FY22 | −$0.16 | n/a | $0.18 | |
| Q3 FY22 | $0.14 | +169% | $0.26 | |
| Q2 FY22 | $0.11 | +108% | $0.17 | |
| Q1 FY22 | $0.09 | +100% | $0.11 | |
| Q4 FY21 | −$0.08 | n/a | $0.07 | |
| Q3 FY21 | $0.05 | +44% | n/a | |
| Q2 FY21 | $0.05 | +63% | n/a | |
| Q1 FY21 | $0.04 | −15% | n/a | |
| Q3 FY20 | $0.04 | n/a | −$9.48 | |
| Q2 FY20 | $0.03 | n/a | −$21.68 | |
| Q1 FY20 | $0.05 | n/a | −$29.39 |
Against its peers
Companies in Drug Manufacturers - General nearest Chemomab Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CMMBChemomab Therapeutics | n/m | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| ARVNArvinas | $0.16 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| PCRXPacira BioSciences | $0.35 | |
| Peer median | $0.85 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Chemomab Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.